Faes Farma : Q2 2021 results above expectations on better cost control but guidance maintained
>Q2 2021 results above expectations on lower SG&A - Faes Farma has reported better-than-expected results in Q2 2021 helped by a favourable comparable basis, with sales in line with our expectations but EBITDA 17% above estimates and core EPS 40% above expectations.Total revenues reached € 97m (+11% y-o-y), with sales of traditional products in Spain regaining traction (+13% y-o-y) reflecting the gradual lifting of the various lockdowns. Nevertheless, EBITDA reach...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.